These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36521913)

  • 1. Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network.
    Gladman DD; Choquette D; Khraishi M; Inman RD; Hussein S; Neish D; Leclerc P
    J Rheumatol; 2023 May; 50(5):641-648. PubMed ID: 36521913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network.
    Inman RD; Choquette D; Khraishi M; Gladman DD; Hussein S; Neish D; Leclerc P
    J Rheumatol; 2023 May; 50(5):634-640. PubMed ID: 36642434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study.
    Benavent D; Muñoz-Fernández S; De la Morena I; Fernández-Nebro A; Marín-Corral J; Castillo Rosa E; Taberna M; Sanabra C; Sastre C;
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231220818. PubMed ID: 38146537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
    Michelsen B; Georgiadis S; Di Giuseppe D; Loft AG; Nissen MJ; Iannone F; Pombo-Suarez M; Mann H; Rotar Z; Eklund KK; Kvien TK; Santos MJ; Gudbjornsson B; Codreanu C; Yilmaz S; Wallman JK; Brahe CH; Möller B; Favalli EG; Sánchez-Piedra C; Nekvindova L; Tomsic M; Trokovic N; Kristianslund EK; Santos H; Löve TJ; Ionescu R; Pehlivan Y; Jones GT; van der Horst-Bruinsma I; Ørnbjerg LM; Østergaard M; Hetland ML
    Arthritis Care Res (Hoboken); 2022 Jul; 74(7):1205-1218. PubMed ID: 33460531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
    Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
    Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry.
    Pombo-Suarez M; Sanchez-Piedra C; Garcia-Magallón B; Pérez-Gómez A; Manrique-Arija S; Martín-Doménech R; Colazo M; Campos C; Campos J; Del Pino-Montes J; Arteaga MJ; Cea-Calvo L; Díaz-González F; Gómez-Reino JJ
    Clin Rheumatol; 2021 Oct; 40(10):3979-3988. PubMed ID: 33907904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs.
    Khraishi MM; Remple VP; Silverberg S; Stewart JC; Florica B; Bessette L
    J Rheumatol; 2022 May; 49(5):454-464. PubMed ID: 35033999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.
    Rahman P; Zummer M; Bessette L; Baer P; Haraoui B; Chow A; Kelsall J; Kapur S; Rampakakis E; Psaradellis E; Lehman AJ; Nantel F; Osborne B; Tkaczyk C
    BMJ Open; 2017 Aug; 7(8):e016619. PubMed ID: 28855200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Young P; Fallon L; Mundayat R; Dina O; Blachley T; Middaugh N; Ogdie A
    Rheumatol Ther; 2024 Apr; 11(2):313-329. PubMed ID: 38252211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
    Michelsen B; Sexton J; Wierød A; Bakland G; Rødevand E; Krøll F; Kvien TK
    Semin Arthritis Rheum; 2020 Feb; 50(1):12-16. PubMed ID: 31358361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
    Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Xu S; Quinn ST; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar A; Østergaard M; Baraliakos X
    Trials; 2022 Sep; 23(1):743. PubMed ID: 36064592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of original and biosimilar etanercept (Enbrel® vs Benepali®) in bDMARD-naïve patients in a real-world cohort of Portugal.
    Pinto AS; Cunha MM; Pinheiro F; Bernardes M; Assunção H; Martins-Martinho J; Tenazinha C; Monteiro AM; Silva S; Martins FR; Silva L; Couto M; Faria M; Araújo F; Fontes T; Santos-Faria D; Tavares-Costa J
    ARP Rheumatol; 2022; 1(2):109-116. PubMed ID: 35810368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design.
    Rombach I; Tillett W; Jadon D; Tucker L; Watson M; Francis A; Sinomati Y; Eldridge L; Dritsaki M; Dutton SJ; Al-Mossawi H; Gullick N; Thompson B; Coates LC
    Trials; 2021 Mar; 22(1):185. PubMed ID: 33663566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Blachley T; Dube B; McLean RR; Kim N; Hur P; Ogdie A
    J Rheumatol; 2022 Jul; 49(7):700-706. PubMed ID: 35428716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
    So A; Inman RD
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
    Iannone F; Semeraro A; Carlino G; Santo L; Bucci R; Quarta L; Maruotti N; Zuccaro C; Marsico A; Falappone PCF; Mazzotta D; Cantatore FP; Muratore M; Lapadula G
    Clin Drug Investig; 2019 Jun; 39(6):565-575. PubMed ID: 30941736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts.
    Möller B; Scholz GA; Amsler J; Ciurea A; Micheroli R; Nissen MJ; Papagiannoulis E; Blapp C; Scherer A; Yawalkar N
    Rheumatology (Oxford); 2024 May; 63(6):1528-1533. PubMed ID: 37676822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.